ANHANG III VO (EU) 2013/944
Index-Nr. | Internationale chemische Bezeichnung | EG-Nr. | CAS-Nr. | Einstufung | Kennzeichnung |
Spezifische Konzentrationsgrenzen M-Faktoren |
Anmerkungen | |||
---|---|---|---|---|---|---|---|---|---|---|
Gefahrenklasse, Gefahrenkategorie und Gefahrenkodierung | Kodierung der Gefahrenhinweise | Piktogramm, Kodierung der Signalworte | Kodierung der Gefahrenhinweise | Kodierung der ergänzenden Gefahrenmerkmale | ||||||
031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 | Carc. 1B | H350 | GHS08 | H350 | |||
STOT RE 1 | H372 (respiratory and haematopoietic systems) | Dgr | H372 (respiratory and haematopoietic systems) | |||||||
050-025-00-6 | trichloromethylstannane | 213-608-8 | 993-16-8 | Repr. 2 | H361d |
GHS08 Wng |
H361d | |||
050-026-00-1 | 2-ethylhexyl 10-ethyl-4-[[2-[(2-ethylhexyl)oxy]-2-oxoethyl]thio]-4-methyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate | 260-828-5 | 57583-34-3 | Repr. 2 | H361d |
GHS08 Wng |
H361d | |||
050-027-00-7 | 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate | 239-622-4 | 15571-58-1 | Repr. 1B | H360D |
GHS08 Dgr |
H360D | |||
601-087-00-3 | 2,4,4-trimethylpentene | 246-690-9 | 25167-70-8 | Flam. Liq. 2 | H225 | GHS02 | H225 | D | ||
Asp. Tox. 1 | H304 | GHS07 | H304 | |||||||
STOT SE 3 | H336 |
GHS08 Dgr |
H336 | |||||||
606-145-00-1 |
sulcotrione (ISO); 2-[2-chloro-4-(methylsulfonyl)benzoyl]cyclohexane-1,3-dione |
99105-77-8 | Repr. 2 | H361d | GHS08 | H361d |
M = 1 M = 10 |
|||
STOT RE 2 | H373 (kidneys) | GHS07 | H373 (kidneys) | |||||||
Skin Sens. 1A | H317 | GHS09 | H317 | |||||||
Aquatic Acute 1 | H400 | Wng | ||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
607-699-00-7 |
bifenthrin (ISO); (2-methylbiphenyl-3-yl)methyl rel-(1R,3R)-3-[(1Z)-2-chloro-3,3,3-trifluoroprop-1-en-1-yl]-2,2-dimethylcyclopropanecarboxylate |
82657-04-3 | Carc. 2 | H351 | GHS06 | H351 |
M = 10000 M = 100000 |
|||
Acute Tox. 3 | H331 | GHS08 | H331 | |||||||
Acute Tox. 2 | H300 | GHS09 | H300 | |||||||
STOT RE 1 | H372 (nervous system) | Dgr | H372 (nervous system) | |||||||
Skin Sens. 1B | H317 | H317 | ||||||||
Aquatic Acute 1 | H400 | |||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
607-700-00-0 |
indoxacarb (ISO); methyl (4aS)-7-chloro-2-{(methoxycarbonyl)[4-(trifluoromethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylate [1] |
173584-44-6 [1] | Acute Tox. 3 | H301 | GHS06 | H301 |
M = 1 M = 1 |
|||
Acute Tox. 4 | H332 | GHS08 | H332 | |||||||
STOT RE 1 | H372 (blood, nervous system, heart) | GHS09 | H372 (blood, nervous system, heart) | |||||||
Skin Sens. 1B | H317 | Dgr | H317 | |||||||
Aquatic Acute 1 | H400 | |||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
reaction mass of (S)- Indoxacarb and (R)- Indoxacarb 75:25; methyl 7-chloro-2-{(methoxycarbonyl)[4-(trifluoromethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylate [2] |
144171-61-9 [2] | |||||||||
607-702-00-1 | dihexyl phthalate | 201-559-5 | 84-75-3 | Repr. 1B | H360FD |
GHS08 Dgr |
H360FD | |||
607-703-00-7 | ammoniumpentadeca- fluorooctanoate | 223-320-4 | 3825-26-1 | Carc. 2 | H351 | GHS08 | H351 | |||
Repr. 1B | H360D | GHS07 | H360D | |||||||
Lact. | H362 | GHS05 | H362 | |||||||
Acute Tox. 4 | H332 | Dgr | H332 | |||||||
Acute Tox. 4 | H302 | H302 | ||||||||
STOT RE 1 | H372 (liver) | H372 (liver) | ||||||||
Eye Dam.1 | H318 | H318 | ||||||||
607-704-00-2 | perfluorooctanoic acid | 206-397-9 | 335-67-1 | Carc. 2 | H351 | GHS08 | H351 | |||
Repr. 1B | H360D | GHS07 | H360D | |||||||
Lact. | H362 | GHS05 | H362 | |||||||
Acute Tox. 4 | H332 | Dgr | H332 | |||||||
Acute Tox. 4 | H302 | H302 | ||||||||
STOT RE 1 | H372 (liver) | H372 (liver) | ||||||||
Eye Dam. 1 | H318 | H318 | ||||||||
612-282-00-8 | octadecylamine | 204-695-3 | 124-30-1 | Asp. Tox. 1 | H304 | GHS05 | H304 |
M = 10 M = 10 |
||
STOT RE 2 | H373 (gastro-intestinal tract, liver, immune system) | GHS08 | H373 (gastro-intestinal tract, liver, immune system) | |||||||
Skin Irrit. 2 | H315 | GHS09 | H315 | |||||||
Eye Dam. 1 | H318 | Dgr | H318 | |||||||
Aquatic Acute 1 | H400 | |||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
612-283-00-3 | (Z)-octadec-9-enylamine | 204-015-5 | 112-90-3 | Acute Tox. 4 | H302 | GHS05 | H302 |
M = 10 M = 10 |
||
Asp Tox. 1 | H304 | GHS07 | H304 | |||||||
STOT SE 3 | H335 | GHS08 | H335 | |||||||
STOT RE 2 | H373 (gastro-intestinal tract, liver, immune system) | GHS09 | H373 (gastro-intestinal tract, liver, immune system) | |||||||
Skin Corr. 1B | H314 | Dgr | H314 | |||||||
Aquatic Acute 1 | H400 | |||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
612-284-00-9 | amines, hydrogenated tallow alkyl | 262-976-6 | 61788-45-2 | Asp Tox. 1 | H304 | GHS08 | H304 |
M = 10 M = 10 |
||
STOT RE 2 | H373 (gastro-intestinal tract, liver, immune system) | GHS05 | H373 (gastro-intestinal tract, liver, immune system) | |||||||
Skin Irrit. 2 | H315 | GHS09 | H315 | |||||||
Eye Dam. 1 | H318 | Dgr | H318 | |||||||
Aquatic Acute 1 | H400 | |||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
612-285-00-4 | amines, coco alkyl | 262-977-1 | 61788-46-3 | Acute Tox. 4 | H302 | GHS05 | H302 |
M = 10 M = 10 |
||
Asp. Tox. 1 | H304 | GHS07 | H304 | |||||||
STOT SE 3 | H335 | GHS08 | H335 | |||||||
STOT RE 2 | H373 (gastro-intestinal tract, liver, immune system) | GHS09 | H373 (gastro-intestinal tract, liver, immune system) | |||||||
Skin Corr. 1B | H314 | Dgr | H314 | |||||||
Aquatic Acute 1 | H400 | |||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
612-286-00-X | amines, tallow alkyl | 263-125-1 | 61790-33-8 | Acute Tox. 4 | H302 | GHS05 | H302 |
M = 10 M = 10 |
||
Asp. Tox. 1 | H304 | GHS07 | H304 | |||||||
STOT RE 2 | H373 (gastro-intestinal tract, liver, immune system) | GHS08 | H373 (gastro-intestinal tract, liver, immune system) | |||||||
Skin Corr. 1B | H314 | GHS09 | H314 | |||||||
Aquatic Acute 1 | H400 | Dgr | ||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
616-206-00-4 |
flufenoxuron (ISO); 1-(4-(2-cloro-α,α,α-p-trifluorotolyloxy)-2-fluorophenyl)-3-(2,6-difluorobenzolyl)urea |
417-680-3 | 101463-69-8 | Lact. | H362 | GHS09 | H362 |
M = 10000 M = 10000 |
||
Aquatic Acute 1 | H400 | Wng | ||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
616-207-00-X | polyhexamethylene biguanide hydrochloride | 27083-27-8 or 32289-58-0 | Carc. 2 | H351 | GHS05 | H351 |
M = 10 M = 10 |
|||
Acute Tox. 4 | H302 | GHS07 | H302 | |||||||
STOT RE 1 | H372 (respiratory tract) (inhalation) | GHS08 | H372 (respiratory tract) (inhalation) | |||||||
Eye Dam. 1 | H318 | GHS09 | H318 | |||||||
Skin Sens. 1B | H317 | Dgr | H317 | |||||||
Aquatic Acute 1 | H400 | |||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
616-208-00-5 |
N-ethyl-2-pyrrolidone; 1-ethylpyrrolidin-2-one |
220-250-6 | 2687-91-4 | Repr. 1B | H360D |
GHS08 Dgr |
H360D | |||
616-209-00-0 |
amidosulfuron (ISO); 3-(4,6-dimethoxypyrimidin-2-yl)-1-((N-methyl-N-methylsulfonylamino)sulfonyl)urea |
407-380-0 | 120923-37-7 | Aquatic Acute 1 | H400 | GHS09 |
M = 100 M = 100 |
|||
Aquatic Chronic 1 | H410 | Wng | H410 | |||||||
616-210-00-6 |
tebufenpyrad (ISO); N-(4-tertbutylbenzyl)- 4-chloro-3-ethyl-1-methyl-1Hpyrazole-5- carboxamide |
119168-77-3 | Acute Tox. 3 | H301 | GHS06 | H301 |
M = 10 M = 10 |
|||
Acute Tox. 4 | H332 | GHS08 | H332 | |||||||
STOT RE 2 | H373 (gastro-intestinal tract) (Oral) | GHS09 | H373 (gastro-intestinal tract) (Oral) | |||||||
Skin Sens. 1B | H317 | Dgr | H317 | |||||||
Aquatic Acute 1 | H400 | |||||||||
Aquatic Chronic 1 | H410 | H410 | ||||||||
616-211-00-1 |
proquinazid (ISO); 6-iodo-2-propoxy-3-propylquinazolin-4(3H)-one |
189278-12-4 | Carc. 2 | H351 | GHS08 | H351 |
M = 1 M = 10 |
|||
Aquatic Acute 1 | H400 | GHS09 | ||||||||
Aquatic Chronic 1 | H410 | Wng | H410 |
© Europäische Union 1998-2021
Tipp: Verwenden Sie die Pfeiltasten der Tastatur zur Navigation zwischen Normen.